| Title | Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma. |
| Publication Type | Journal Article |
| Year of Publication | 2025 |
| Authors | Kshirsagar RS, Eide JG, Harris J, Abiri A, Beswick DM, Chang EH, Fung N, Hong M, Johnson BJ, Kohanski MA, Le CH, Lee JT, Nabavizadeh SA, Obermeyer IP, Pandrangi VC, Pinheiro-Neto CD, Smith TL, Snyderman CH, Suh JD, Wang EW, Wang MB, Choby G, Geltzeiler M, Lazor J, Mitchell TC, Kuan EC, Palmer JN, Adappa ND |
| Journal | Am J Rhinol Allergy |
| Volume | 39 |
| Issue | 2 |
| Pagination | 102-108 |
| Date Published | 2025 Mar |
| ISSN | 1945-8932 |
| Keywords | Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Combined Modality Therapy, Female, Humans, Immunotherapy, Ipilimumab, Male, Melanoma, Middle Aged, Nasal Mucosa, Nivolumab, Paranasal Sinus Neoplasms, Retrospective Studies, Treatment Outcome |
| Abstract | BACKGROUND: Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma. OBJECTIVE: We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma. METHODS: A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded. RESULTS: 52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT ( = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab ( = 17, 32.7%) or pembrolizumab ( = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively. CONCLUSION: Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response. |
| DOI | 10.1177/19458924241308953 |
| Alternate Journal | Am J Rhinol Allergy |
| PubMed ID | 39782303 |
Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma.
Faculty Reference:
Eugene H. Chang, MD
Christopher Le, MD, FACS